16Jun 2025
SGLT2 Inhibitors Outperform DPP-4 Inhibitors in Reducing HbA1c Variability and Improving Cardiorenal Outcomes

SGLT2 Inhibitors Outperform DPP-4 Inhibitors in Reducing HbA1c Variability and Improving Cardiorenal Outcomes

In high HbA1c variability type 2 diabetes patients, SGLT2 inhibitors significantly reduced glycemic variability and lowered risks of cardiovascular and renal events compared to DPP-4 inhibitors, according to a large territory-wide study from Hong Kong.

  • #endo-diabetology

Like

Save

Share